Browse by Poster Presenter

Type here to filter the list

S
S. Okuma, Hitomi

Department of Medical Oncology, National Cancer Center Hospital
(P 147) ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Hitomi S. Okuma
Favorite
Saadatzadeh, M. Reza

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
M. Reza Saadatzadeh
Favorite
Saba, Karim

Lund University
(P 014) A PLETHORA OF DISEASE-ASSOCIATED ALTERATIONS IN OSTEOSARCOMA
Karim Saba
Favorite
(P 024) GENETIC REARRANGEMENTS IN 12Q-AMPLIFIED OSTEOSARCOMA RESULT IN ECTOPIC GENE EXPRESSION THROUGH TRANSPOSITION OF REGULATORY ELEMENTS AND SELECTIVE AMPLIFICATION
Karim Saba
Favorite
Sabnis, Amit

University of California
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Amit Sabnis
Favorite
Sachs, Elizabeth

Duke
(P 034) REGIONAL ANESTHESIA IMPROVES METASTASIS FREE SURVIVAL AFTER SURGICAL RESECTION OF BONE SARCOMAS
Elizabeth Sachs
Favorite
Sachs, Jessica

Cogent Biosciences
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Jessica Sachs
Favorite
Sahovaler, Axel

Division of Head and Neck Surgery, Princess Margaret Hospital, University of Toronto, Ontario, Canada
(P 290) OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Axel Sahovaler
Favorite
Sairyo, Koichi

Department of Orthopedics Institute of Biomedical Sciences
(P 275) ASSESSMENT OF SURGICAL MARGIN CLASSIFICATION FOR SOFT TISSUE SARCOMA: DEFINITIONS OF ADEQUATE MARGINS SYSTEM FOR PLANNING AND EVALUATION
Koichi Sairyo
Favorite
Saito, Ayumi

Department of Medical Oncology, National Cancer Center Hospital
(P 147) ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Ayumi Saito
Favorite
Sakai, Tomohisa

Nagoya University Hospital
(P 262) CLINICAL RESULTS OF ACTIVE SURVEILLANCE FOR EXTRA ABDOMINAL DESMOID TYPE FIBROMATOSIS
Tomohisa Sakai
Favorite
(P 322) PHASE 2 SINGLE-ARM CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF AURANOFIN IN ADULT PATIENTS WITH PROGRESSIVE DESMOID
Tomohisa Sakai
Favorite
Saka, Sinem

European Molecular Biology Laboratory (EMBL)
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Sinem Saka
Favorite
Salazar Arcila, Carolina

University of Calgary
(P 128) INVESTIGATING THE ROLE OF MACROPHAGES IN A MURINE MODEL OF SOFT TISSUE SARCOMA
Carolina Salazar Arcila
Favorite
(P 142) USE OF SMALL MOLECULE STIMULATE OF TYPE-1 INTERFERON GENES (STING) AGONIST IMMUNOTHERAPY FOR CANINE SARCOMA: A CROSS-SPECIES ANALYSIS
Carolina Salazar Arcila
Favorite
Sallan, Sarah

Dana-Farber Cancer Institute
(P 239) FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS
Sarah Sallan
Favorite
Salvi, Omkar

TATA MEMORIAL HOSPITAL
(P 03) DEMOGRAPHICS, PRACTICE PATTERNS, CHALLENGES AND OUTCOMES OF SYNOVIAL SARCOMA PATIENTS FROM A TERTIARY CARE CENTRE FROM A LARGE LOW-MIDDLE INCOME COUNTRY
Omkar Salvi
Favorite
Samà, Laura

Humanitas Research Hospital
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Laura Samà
Favorite
(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE
Laura Samà
Favorite
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Laura Samà
Favorite
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Laura Samà
Favorite
Samiei, Alireza

University of California, Los Angeles
(P 243) MUTATIONAL ANALYSIS OF PRIMARY AND ADVANCED CHORDOMA TISSUE USING NEXT-GENERATION SEQUENCING
Alireza Samiei
Favorite
San Román Gil, María

Department of Medical Oncology, Ramón y Cajal University Hospital
(P 157) MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
María San Román Gil
Favorite
Sanchez Esquer, Ignacio

Hospital Universitario Virgen de la Arrixaca
(P 219) PROGNOSTIC VALUE OF HEMATOLOGICAL MARKERS IN LEIOMYOSARCOMA
Ignacio Sanchez Esquer
Favorite
(P 281) CUTANEOUS SARCOMA: CASE SERIES DESCRIPTION AND ANALYSIS OF FACTORS RELATED TO AN UNFAVORABLE EVOLUTION
Ignacio Sanchez Esquer
Favorite
Sanchez-Henarejos, Pilar

HCU VIRGEN ARRIXACA
(P 318) NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA. UPDATED NASAR STUDY
Pilar Sanchez-Henarejos
Favorite
Sancho Marquez, Maria Pilar

Hospital Universitario Virgen del Rocío
(P 267) EFFICACY OF SORAFENIB IN PRETREATED DESMOID TUMORS. EXPERIENCE OF A HIGH-VOLUME CENTER.
Maria Pilar Sancho Marquez
Favorite
Sanfilippo, Roberta

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Roberta Sanfilippo
Favorite
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Roberta Sanfilippo
Favorite
Sangalli, Claudia

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Claudia Sangalli
Favorite
(P 145) A RETROSPECTIVE CASE SERIES ANALYSIS OF 22 RHABDOMYOSARCOMA PATIENTS WITH SPINDLE-CELL/SCLEROSING MORPHOLOGY
Claudia Sangalli
Favorite
(P 203) MULTIDISCIPLINARY APPROACH OF ADVANCED-STAGE ALVEOLAR RHABDOMYOSARCOMA OF THE MAXILLARY SINUS IN ADULTS: A CASE REPORT
Claudia Sangalli
Favorite
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Claudia Sangalli
Favorite
Santini, Daniele

University of Rome “Sapienza”
(P 185) PHARMACOLOGICAL INHIBITION OF GLYOXALASE-1 AS NOVEL THERAPEUTIC STRATEGY TO POTENTIATE TRABECTEDIN ANTI-TUMOR EFFECT IN SOFT TISSUE SARCOMA PRECLINICAL MODELS
Daniele Santini
Favorite
Santori, Ilaria

Humanitas University
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Ilaria Santori
Favorite
(P 065) AN APP TO PREDICT MITOTIC COUNT ON THE SURGICAL SPECIMEN OF GIST.
Ilaria Santori
Favorite
(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE
Ilaria Santori
Favorite
Santoro, Armando

Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele - Milan, Italy.
(P 02) CLINICAL CHARACTERISTICS AND OUTCOME OF ADOLESCENT AND YOUNG ADULTS SOFT TISSUE AND BONE SARCOMAS AT AN ADULT CANCER CENTER: THE BENEFITS OF A DEDICATED, MULTIDISCIPLINARY MANAGEMENT
Armando Santoro
Favorite
(P 08) HOW TO DEVELOP AN ADOLESCENT AND YOUNG PROGRAM IN AN ADULT CANCER CENTER: THE HUMANITAS RESEARCH HOSPITAL EXPERIENCE
Armando Santoro
Favorite
(P 117) SHOULD REGORAFENIB BE PRESCRIBED AS A CONTINUOUS SCHEDULE AT LEAST IN GASTROINTESTINAL STROMAL TUMORS (GIST)?
Armando Santoro
Favorite
(P 247) PROGNOSTIC VALUE OF MITOTIC COUNT IN NON-UTERINE LEIOMYOSARCOMAS: A MONOCENTRIC RETROSPECTIVE STUDY.
Armando Santoro
Favorite
Saquib, Mostafa

Research Institute of the McGill University Health Centre
(P 030) OSTEOSARCOMA PATIENT-DERIVED-XENOGRAFTS A RELEVANT MODEL TO STUDY CHEMOTHERAPEUTIC AND METASTATIC EVENTS
Mostafa Saquib
Favorite
Sargos, Paul

Department of Radiotherapy, Institut Bergonié
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Paul Sargos
Favorite
Sarkar, Laboni

Tata Memorial Hospital, Mumbai
(P 09) OUTCOMES, PROGNOSTIC FACTORS AND TREATMENT COMPLIANCE IN OSTEOSARCOMA CASES TREATED WITH AN INDIGENOUS, LOW-COST PROTOCOL, OGS-12, IN A TERTIARY CARE CANCER CENTRE IN INDIA
Laboni Sarkar
Favorite
Sarre-Lazcano, Catherine

Department of Surgery, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Catherine Sarre-Lazcano
Favorite
Sarro, Emily

Memorial Sloan Kettering Cancer Center
(P 307) ADOLESCENT AND YOUNG ADULT SARCOMA TREATMENT HARMONIZATION: AYA MAP FOR OSTEOSARCOMA
Emily Sarro
Favorite
Sartini, Sara

University of California, Los Angeles
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Sara Sartini
Favorite
Sartoski, Shauna

Cleveland Clinic
(P 311) VIRTUAL VISITS FOR SARCOMAS AND OTHER RARE CANCERS INCLUDING DESMOIDS: THE EVOLUTION OF INFORMATION AND EDUCATIONAL OPPORTUNITIES TO IMPOVE HEALTH: 2017-2022
Shauna Sartoski
Favorite
Sassi, Slim

Massachusetts General Hospital, Harvard Medical School
(P 243) MUTATIONAL ANALYSIS OF PRIMARY AND ADVANCED CHORDOMA TISSUE USING NEXT-GENERATION SEQUENCING
Slim Sassi
Favorite
Saumet, Laure

CHU Montpellier
(P 026) IS THERE STILL A PLACE FOR BONE MARROW SAMPLING IN VERY HIGH RISK EWING SARCOMA? ROLE OF FDG PET/CT IN THE INITIAL STAGING OF VERY HIGH RISK EWING SARCOMA IN A PROSPECTIVE PHASE II MULTICENTRIC STUDY.
Laure Saumet
Favorite
Sayyed, Raza

The Royal Marsden Hospital
(P 085) RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Raza Sayyed
Favorite
Sbaraglia, Marta

Department of Pathology, Azienda Ospedaliero Universitaria, University of Padua, Padua, Italy
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Marta Sbaraglia
Favorite
Scarzello, Giovanni

Veneto Institute of Oncology IOV – IRCCS
(P 06) GONADOTOXICITY RISK EVALUATION AND REPRODUCTIVE OUTCOMES IN YOUNG ADULTS WITH SOFT TISSUE AND BONE SARCOMA TREATED WITH CHEMOTHERAPY AND/OR RADIATION THERAPY: A SINGLE CENTER RETROSPECTIVE STUDY
Giovanni Scarzello
Favorite
Schaefer, Christiane

University Hospital Essen, Pediatrics III, Essen, Germany
(P 040) TWO RARE SIDES OF ONE RARE DISEASE: EWING SARCOMA WITH AND AS SECONDARY MALIGNANCIES FROM THE EPIDEMIOLOGICAL AND CLINICAL ANALYSIS OF AN INTERNATIONAL TRIAL REGISTRY
Christiane Schaefer
Favorite
Schaefer, Inga-Marie

Brigham and Women's Hospital
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Inga-Marie Schaefer
Favorite
Scheipl, Susanne

Department of Orthopaedics and Trauma, Medical University of Graz
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Susanne Scheipl
Favorite
Schildhaus, Hans-Ulrich

Institute of Pathology, West German Cancer Center, University Hospital Essen
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Hans-Ulrich Schildhaus
Favorite
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Hans-Ulrich Schildhaus
Favorite
Schmid, Anita

Aadi Bioscience
(P 156) MANAGEMENT OF ADVERSE EVENTS IN THE AMPECT TRIAL OF NAB-SIROLIMUS FOR THE TREATMENT OF ADVANCED MALIGNANT PECOMA
Anita Schmid
Favorite
(P 167) STUDY-END ANALYSIS FROM AMPECT, AN OPEN-LABEL, PHASE 2 REGISTRATION TRIAL OF PATIENTS WITH ADVANCED MALIGNANT PECOMA TREATED WITH nab-SIROLIMUS, SHOWING DURABILITY OF RESPONSE AND LONG-TERM SAFETY
Anita Schmid
Favorite
(P 313) A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Anita Schmid
Favorite
Schoedel, Karen

University of Pittsburgh Medical Center
(P 087) RATING THE EFFICACY OF DIAGNOSTIC IMAGING STUDIES PERFORMED FOR THE WORK-UP OF MUSCULOSKELETAL MASSES
Karen Schoedel
Favorite
Schoenborn-Kellenberger, Oliver

C4 Therapeutics
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Oliver Schoenborn-Kellenberger
Favorite
Schöffski, Patrick

Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute
(P 182) NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH
Patrick Schöffski
Favorite
(P 198) XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Patrick Schöffski
Favorite
(P 314) A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1
Patrick Schöffski
Favorite
(P 316) FIRST-IN-HUMAN PHASE 1/1B STUDY OF IDRX-42, A NOVEL ORAL TYROSINE KINASE KIT INHIBITOR, IN PARTICIPANTS WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMORS
Patrick Schöffski
Favorite
Scholl, Claudia

German Cancer Research Center
(P 231) COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Claudia Scholl
Favorite
Schrage, Yvonne

Netherland Cancer Institute
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Yvonne Schrage
Favorite
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Yvonne Schrage
Favorite
Schreuder, Hendrik

Radboud University, Nijmegen, Netherlands
(P 038) TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY
Hendrik Schreuder
Favorite
Schuck, Virna

Certara
(P 187) PRECLINICAL VALIDATION OF TARGET ENGAGEMENT ASSAYS AND INVESTIGATION OF MECHANISTIC IMPACTS OF FHD-609, A CLINICAL-STAGE BRD9 DEGRADER BEING DEVELOPED FOR THE TREATMENT OF SYNOVIAL SARCOMA
Virna Schuck
Favorite
Schuetze, Scott

Department of Internal Medicine, University of Michigan, Rogel Cancer Center
(P 314) A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1
Scott Schuetze
Favorite
Schuler, Martin

Department of Medical Oncology, West German Cancer Center, University Hospital Essen
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Martin Schuler
Favorite
Schulte, Brian

UCSF Helen Diller Family Comprehensive Cancer Center
(P 313) A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Brian Schulte
Favorite
Schulz, Tom

Faculty of Chemistry and Chemical Biology, TU Dortmund University, Dortmund, Germany
(P 108) NILOTINIB REVISITED: SALVAGE USE IN PATIENTS WITH SEVERE IMATINIB-TOXICITY
Tom Schulz
Favorite
Schut, Anne-Rose

Erasmus Medical Center Rotterdam
(P 044) AUTOMATIC SEGMENTATION USING DEEP LEARNING TO DISTINGUISH BETWEEN 9 TYPES OF SOFT-TISSUE TUMORS WITH RADIOMICS
Anne-Rose Schut
Favorite
Schutz, Makena

Institute for Limb Preservation, Presbyterian/St. Luke’s Medical Center
(P 294) PERCUTANEOUS STABILIZATION OF PATHOLOGIC FRACTURES OF THE PELVIS AND SACRUM
Makena Schutz
Favorite
Schwartz, Donald

Texas Oncology
(P 248) RESULTS OF A NEOADJUVANT REGIMEN USING A FIXED DOSE OF ADRIAMYCIN AS AN ELECTRON AFFINIC AGENT WITH 27GY FOLLOWED BY WIDE LOCAL RESECTION OF SOFT TISSUE SARCOMAS
Donald Schwartz
Favorite
Schwartz, Gary

Columbia University Herbert Irving Comprehensive Cancer Center
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Gary Schwartz
Favorite
(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS
Gary Schwartz
Favorite
Sciot, Raf

Department of Pathology, KU Leuven and University Hospitals Leuven
(P 182) NOVEL TISSUE MICROARRAY (TMA) PLATFORM AS A TOOL FOR COLLABORATIVE SOFT TISSUE SARCOMA (STS) RESEARCH
Raf Sciot
Favorite
(P 198) XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Raf Sciot
Favorite
Scoazec, Jean-Yves

CLCC gustave roussy
(P 048) IMMUNE INFILTRATION AS PROGNOSTIC FACTORS IN METASTATIC LEIOMYOSARCOMA
Jean-Yves Scoazec
Favorite
(P 060) TOWARD A NEW GENOMIC AND CLINICO-PATHOLOGIC CLASSIFICATION OF UTERINE ADENOSARCOMAS
Jean-Yves Scoazec
Favorite
Sears, Timothy

Stanford Univeristy
(P 130) MONITORING SOFT TISSUE SARCOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITION AND CRYOTHERAPY WITH CIRCULATING TUMOR DNA ANALYSIS
Timothy Sears
Favorite
Sebio García, Ana

Hospital de la Santa Creu i Sant Pau
(P 225) TRABECTEDIN WITH CONCOMITANT RADIATION THERAPY FOR PATIENTS WITH RESECTABLE RETROPERITONEAL LIPOSARCOMA OR LEIOMYOSARCOMA: A PHASE I/II TRIAL OF SPANISH (GEIS), ITALIAN (ISG) AND FRENCH (FSG) GROUPS
Ana Sebio García
Favorite
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Ana Sebio García
Favorite
Seddon, Beatrice

University College London Hospitals, NHS Foundation Trust
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Beatrice Seddon
Favorite
Seetharam, Mahesh

Department of Hematology and Oncology, Mayo Clinic
(P 202) LONG-TERM EXPERIENCE WITH INTRAOPERATIVE ELECTRON RADIATION THERAPY BOOST IN EXTREMITY SARCOMA
Mahesh Seetharam
Favorite
Seidensticker, Max
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Max Seidensticker
Favorite
Sekuła, Michał

Faculty of Medicine, Medical University of Warsaw
(P 166) SARCOMA BRAIN METASTASES: EXPERIENCE AT A SINGLE INSTITUTION
Michał Sekuła
Favorite
Seldom, Crystal

Sylvester Comprehensive Cancer Center
(P 070) COMPLETE PATHOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENT IN SOFT TISSUE SARCOMA. A SINGLE INSTITUTION EXPERIENCE.
Crystal Seldom
Favorite
Selich-Anderson, Julia

Abigail Wexner Research Institute at Nationwide Children's Hospital
(P 229) CHARACTERIZING THE MICROSATELLITE-BINDING FUNCTION OF EWS-FLI AND ETV6 IN EWING SARCOMA
Julia Selich-Anderson
Favorite
Seligson, Nathan

University of Florida
(P 177) GENOMIC LANDSCAPE OF RARE EWSR1 FUSIONS
Nathan Seligson
Favorite
(P 256) TUMOR MUTATIONAL BURDEN AND MICROSATELLITE INSTABILITY IN LEIOMYOSARCOMA
Nathan Seligson
Favorite
Selmic, Laura

Department of Veterinary Clinical Sciences, The Ohio State University College of Veterinary Medicine
(P 171) CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE
Laura Selmic
Favorite
Sengupta, Anita

University of Texas Southwestern Medical Center
(P 104) INFANTILE EXTRARENAL SPINDLE CELL MESENCHYMAL NEOPLASMS WITH TARGETABLE EGFR KINASE DOMAIN DUPLICATIONS
Anita Sengupta
Favorite
Senne, Lane

Inhibrx, Inc
(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Lane Senne
Favorite
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Lane Senne
Favorite
Serrano, César

Vall D'hebron Institute of Oncology
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
César Serrano
Favorite
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
César Serrano
Favorite
Serrata, Matthew

Wyss Institute for Biologically Inspired Engineering, Harvard University
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Matthew Serrata
Favorite
Setty, Bhuvana

Nationwide Children's Hospital
(P 027) LEPTOMENINGEAL ENHANCEMENT WITH NEUROLOGIC CHANGES IN PEDIATRIC BONE SARCOMA PATIENTS: A DIAGNOSTICAL CHALLENGE
Bhuvana Setty
Favorite
(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Bhuvana Setty
Favorite
Sevilla, Isabel

Investigación Clínica y Traslacional en Cáncer/Instituto de Investigaciones Biomédicas de Málaga (IBIMA)/Hospitales Universitarios Regional y Virgen de la Victoria
(P 161) PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Isabel Sevilla
Favorite
Seyedin, Steven

Department of Radiation Oncology, University of California Irvine
(P 199) A STUDY OF PRE- AND POST-TREATMENT NEUTROPHIL COUNTS, LYMPHOCYTE COUNTS, AND NEUTROPHIL-TO-LYMPHOCYTE RATIOS IN PATIENTS WITH SOFT TISSUE SARCOMA UNDERGOING RADIOTHERAPY
Steven Seyedin
Favorite
Shackelford, David

UCLA Health
(P 173) DYSREGULATION OF MITOCHONDRIAL DYNAMICS IN WELL-DIFFERENTIATED/DEDIFFERENTIATED LIPOSARCOMA PROVIDES A UNIQUE SUSCEPTABILITY TO NOVEL THERAPY
David Shackelford
Favorite
Shafer, Amanda

University of Michigan
(P 139) T-CELL PROFILING IN HIGH GRADE SARCOMAS
Amanda Shafer
Favorite
Shah, Nilay

Nationwide Children's Hospital
(P 237) EVOLUTIONARILY INSPIRED THERAPY FOR NEWLY DIAGNOSED, METASTATIC, FUSION POSITIVE RHABDOMYOSARCOMA, TRIAL IN PROGRES, NCT04388839, A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Nilay Shah
Favorite
Shah, Rachana

Children's Hospital Los Angeles
(P 037) SURVIVAL OUTCOMES AND POST-SURGICAL MORBIDITY BASED ON SURGICAL APPROACH TO PULMONARY METASTASECTOMY IN PATIENTS WITH OSTEOSARCOMA
Rachana Shah
Favorite
(P 045) DETECTION OF CELL-FREE TUMOR DNA IN PATIENTS WITH NEWLY DIAGNOSED PEDIATRIC BONE AND SOFT TISSUE SARCOMAS
Rachana Shah
Favorite
Shaikh, Furqan

Hospital for Sick Children
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Furqan Shaikh
Favorite
Shamai, Sivan
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Sivan Shamai
Favorite
Shan, Boyao

Abbisko Therapeutics
(P 164) PRELIMINARY PHASE 1B RESULTS OF ABSK021 FOR ADVANCED TENOSYNOVIAL GIANT CELL TUMOR: SIGNIFICANT ANTITUMOR ACTIVITY AND FAVOURABLE SAFETY PROFILE
Boyao Shan
Favorite
Shannon, Harlan

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Harlan Shannon
Favorite
Shannon, Nicholas

National Cancer Centre Singapore
(P 090) TEN-YEAR INCIDENCE AND MORTALITY OF SOFT TISSUE SARCOMAS IN THE NATIONAL CANCER CENTRE SINGAPORE, FROM 2012 TO 2021
Nicholas Shannon
Favorite
(P 196) THERAPEUTIC VULNERABILITY AND RESISTANCE DURING PROGRESSION OF AN AGGRESSIVE SOLITARY FIBROUS TUMOUR
Nicholas Shannon
Favorite
Sharma, Ashwyn

University of California, San Diego
(P 100) COPY NUMBER ALTERATIONS IN CDKN2A AND CDKN2B ARE ASSOCIATED WITH WORSENED OVERALL SURVIVAL IN PATIENTS WITH GIST
Ashwyn Sharma
Favorite
Sharma, Maitreyi

Deciphera Pharmaceuticals, LLC
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Maitreyi Sharma
Favorite
(P 116) SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE
Maitreyi Sharma
Favorite
Shea, Reilly

Atrium Health/Levine Cancer Institute
(P 261) CLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH DESMOID TUMORS: A LARGE SINGLE INSTITUTION RETROSPECTIVE SERIES
Reilly Shea
Favorite
Shenasa, Elahe

University of British Columbia
(P 129) MATURE DENDRITIC CELLS ON TISSUE MICROARRAY CORES CORRELATE WITH THE PRESENCE OF ADJACENT TERTIARY LYMPHOID STRUCTURES IN EPITHELIOID SARCOMA
Elahe Shenasa
Favorite
Shen, Jingnan

Department of Musculoskeletal Oncology Center, The First Affiliated Hospital of Sun Yat-sen University
(P 164) PRELIMINARY PHASE 1B RESULTS OF ABSK021 FOR ADVANCED TENOSYNOVIAL GIANT CELL TUMOR: SIGNIFICANT ANTITUMOR ACTIVITY AND FAVOURABLE SAFETY PROFILE
Jingnan Shen
Favorite
Shen, Lin

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute
(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Lin Shen
Favorite
Shenoy, Archana

The Ohio State University and Nationwide Children's Hospital
(P 155) LATE EVENTS OCCURRING AFTER 5 YEARS IN PEDIATRIC RHABDOMYOSARCOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
Archana Shenoy
Favorite
Shepard, Dale

Cleveland Clinic Taussig Cancer Institute
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Dale Shepard
Favorite
Sherman, Matthew

Deciphera Pharmaceuticals, LLC
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Matthew Sherman
Favorite
(P 116) SAFETY AND EFFICACY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: LONG-TERM PHASE 1 UPDATE
Matthew Sherman
Favorite
Sherman, Scott

University of Iowa Hospitals & Clinics
(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Scott Sherman
Favorite
Shern, John

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute
(P 05) GENETIC ANALYSIS OF ADULT RMS: ARE THERE MOLECULAR ALTERATIONS THAT DRIVE INFERIOR OUTCOMES?
John Shern
Favorite
Shimada, Eijiro

Duke University
(P 125) EFFECTIVENESS OF PERIPHERAL BLOOD IMMUNE-RELATED MARKERS IN SELECTING NOVEL THERAPEUTIC AGENTS FOR ADVANCED SOFT TISSUE SARCOMA
Eijiro Shimada
Favorite
Shimizu, Junya

Sapporo Medical University School of Medicine
(P 084) PROGNOSTIC FACTORS IN PATIENTS WITH DISTANT SOFT TISSUE METASTASIS OF CARCINOMA
Junya Shimizu
Favorite
(P 285) IMPACT OF ACRIDINE ORANGE IN PATIENTS WITH LOCAL RECURRENT SOFT TISSUE SARCOMA
Junya Shimizu
Favorite
Shimoi, Tatsunori

Department of Medical Oncology, National Cancer Center Hospital
(P 147) ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Tatsunori Shimoi
Favorite
(P 150) CLINICAL CHARACTERISTICS OF PRIMARY CUTANEOUS AND SUBCUTANEOUS EWING SARCOMA FAMILY OF TUMORS
Tatsunori Shimoi
Favorite
Shin, Kabsoo

Seoul St. Mary’s Hospital, The Catholic University of Korea
(P 153) IFOSFAMIDE/ETOPOSIDE/CARBOPLATIN REGIMEN AS A POST DOXORUBICIN TREATMENT IN METASTATIC OR RECURRENT SOFT TISSUE SARCOMA
Kabsoo Shin
Favorite
Shivsaran, Sushma

Tata Memorial Hospital Mumbai
(P 09) OUTCOMES, PROGNOSTIC FACTORS AND TREATMENT COMPLIANCE IN OSTEOSARCOMA CASES TREATED WITH AN INDIGENOUS, LOW-COST PROTOCOL, OGS-12, IN A TERTIARY CARE CANCER CENTRE IN INDIA
Sushma Shivsaran
Favorite
Shlien, Adam

Research Institute, The Hospital for Sick Children
(P 191) SYNERGISTIC ACTIVITY OF PARP INHIBITORS IN COMBINATION WITH STANDARD CHEMOTHERAPY IN LEIOMYOSARCOMA
Adam Shlien
Favorite
Sholler, Chloe

Atrium Health - Levine Children's Hospital
(P 246) PANOBINOSTAT DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Chloe Sholler
Favorite
Shulman, David

Dana-Farber Cancer Institute
(P 010) SPECTRUM OF EWING-LIKE FUSIONS AND SECONDARY GENOMIC ALTERATIONS FROM A LARGE NEXT GENERATION SEQUENCING (NGS) COMPREHENSIVE GENOMIC PROFILING (CGP) DATABASE
David Shulman
Favorite
Shultz, David

Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto; CanSaRCC, Princess Margaret Cancer Centre
(P 068) CLINICO-DEMOGRAPHIC CHARACTERISTICS AND OUTCOMES OF RADIATION-INDUCED SARCOMAS: A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) STUDY
David Shultz
Favorite
Sicinska, Ewa

Dana-Farber Cancer Institute
(P 099) CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Ewa Sicinska
Favorite
Sicklick, Jason

UC San Diego Health
(P 096) AN OPEN-LABEL, PHASE 2 EFFICACY STUDY OF TEMOZOLOMIDE IN ADVANCED SUCCINATE DEHYDROGENASE-MUTANT/DEFICIENT GASTROINTESTINAL STROMAL TUMOR
Jason Sicklick
Favorite
(P 100) COPY NUMBER ALTERATIONS IN CDKN2A AND CDKN2B ARE ASSOCIATED WITH WORSENED OVERALL SURVIVAL IN PATIENTS WITH GIST
Jason Sicklick
Favorite
Sicoli, Federico

Sarcoma Surgery Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 056) PROGNOSTIC VALUE OF VESSELS ENCAPSULATING TUMOR CLUSTERS (VETC) IN SARCOMA.
Federico Sicoli
Favorite
(P 057) SARCOMA MICROENVIRONMENT CHARACTERIZATION: CLINICOPATHOLOGICAL ANALYSIS OF ONE-HUNDRED TWENTY-SIX CASES
Federico Sicoli
Favorite
(P 065) AN APP TO PREDICT MITOTIC COUNT ON THE SURGICAL SPECIMEN OF GIST.
Federico Sicoli
Favorite
(P 106) LAPAROSCOPY IN GASTRIC GIST: RETROSPECTIVE PRE-POST COMPARISON ANALYSIS OF SHORT TERM OUTCOMES ON A CONSECUTIVE SERIES OF 95 CASES FROM A TERTIARY REFERRAL CENTRE
Federico Sicoli
Favorite
(P 224) THE ROLE OF NEOADJUVANT CHEMOTHERAPY IN RETROPERITONEAL SARCOMA. A CASE-MATCHED ANALYSIS.
Federico Sicoli
Favorite
(P 247) PROGNOSTIC VALUE OF MITOTIC COUNT IN NON-UTERINE LEIOMYOSARCOMAS: A MONOCENTRIC RETROSPECTIVE STUDY.
Federico Sicoli
Favorite
Sieverling, Lina

Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ)
(P 231) COMPREHENSIVE MOLECULAR PROFILING OF FOLLICULAR DENDRITIC CELL SARCOMA
Lina Sieverling
Favorite
Sigalotti, Luca

Centro di Riferimento Oncologico di Aviano (CRO), IRCCS
(P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Luca Sigalotti
Favorite
Silva, Tulio

LUMC
(P 230) CHARACTERIZING TISSUE-BASED CHANGES DURING AND AFTER RADIOTHERAPY IN MYXOID LIPOSARCOMAS IN THE DOREMY TRIAL
Tulio Silva
Favorite
Silveri, Claudio

Unidad de Patología Oncológica Musculo Esquelética, Instituto Nacional de Ortopedia y Traumatología
(P 077) FREEZING IN FLORIDA: ARE WE READY FOR DIVERSITY?
Claudio Silveri
Favorite
(P 309) THE ONCOLOGY ORTHOPEDIST ROLE: WHERE DO WE FIT?
Claudio Silveri
Favorite
Simmons, Christine

BC Cancer
(P 074) EWING SARCOMA AND RHABDOMYOSARCOMA PATIENT OUTCOME VARIATIONS BASED ON TREATMENT CENTRE VOLUME
Christine Simmons
Favorite
(P 165) REAL- WORLD EXPERIENCE OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH RECURRENT BONE TUMOURS (BT): A CANSARCC STUDY
Christine Simmons
Favorite
Simonetti, Sonia

Campus Bio-Medico University of Rome
(P 185) PHARMACOLOGICAL INHIBITION OF GLYOXALASE-1 AS NOVEL THERAPEUTIC STRATEGY TO POTENTIATE TRABECTEDIN ANTI-TUMOR EFFECT IN SOFT TISSUE SARCOMA PRECLINICAL MODELS
Sonia Simonetti
Favorite
Sims, Emily

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Emily Sims
Favorite
Singer, Samuel

Memorial Sloan Kettering Cancer Center
(P 241) INVESTIGATING THE EVOLUTION OF CELL STATES IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING A GENETICALLY ENGINEERED MOUSE MODEL
Samuel Singer
Favorite
Singh, Arun

University of California at Los Angeles
(P 015) A SIGNAL FINDING STUDY OF NIVOLUMAB AND RELATLIMAB IN ADVANCED CHORDOMA
Arun Singh
Favorite
(P 039) THE GENOMIC AND IMMUNE LANDSCAPE OF OSTEOSARCOMA
Arun Singh
Favorite
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Arun Singh
Favorite
(P 193) TARGETING THE PAX-FOXO FUSION VIA HDAC INHIBITION IN RHABDOMYOSARCOMA
Arun Singh
Favorite
(P 268) INITIAL RESULTS OF PHASE 2/3 TRIAL OF AL102 FOR TREATMENT OF DESMOID TUMORS (DT)
Arun Singh
Favorite
Sinnaeve, Friedl

UZ Leuven
(P 198) XENOSARC: A PANEL OF PATIENT-DERIVED XENOGRAFT (PDX) MODELS OF SOFT TISSUE SARCOMA FOR PRECLINICAL DRUG EVALUATION
Friedl Sinnaeve
Favorite
Sinn, Anthony

Indiana University
(P 192) TARGETING PI3K/MTOR MITIGATES RESISTANCE TO CDK4/6 INHIBITION IN RB-PROFICIENT PEDIATRIC AND AYA OSTEOSARCOMAS
Anthony Sinn
Favorite
Siontis, Brittany

Mayo Clinic
(P 278) ACUTE CARDIAC CHANGES IN PEDIATRIC AND YOUNG ADULT SOLID TUMOR PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
Brittany Siontis
Favorite
Siracusano, Licia Vanessa

Medical Oncology and Hematology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy
(P 117) SHOULD REGORAFENIB BE PRESCRIBED AS A CONTINUOUS SCHEDULE AT LEAST IN GASTROINTESTINAL STROMAL TUMORS (GIST)?
Licia Vanessa Siracusano
Favorite
Siveke, Jens

Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen
(P 176) FIBROBLAST ACTIVATION PROTEIN ALPHA AS THERANOSTIC TARGET IN SARCOMA
Jens Siveke
Favorite
Skoczylas, Jacek

Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Jacek Skoczylas
Favorite
Slamon, Dennis

University of California, Los Angeles
(P 193) TARGETING THE PAX-FOXO FUSION VIA HDAC INHIBITION IN RHABDOMYOSARCOMA
Dennis Slamon
Favorite
Slotkin, Emily

Memorial Sloan Kettering Cancer Center
(P 144) A PHASE 1/2 DOSE ESCALATION/EXPANSION STUDY OF ZN-C3 PLUS GEMCITABINE IN RELAPSED/REFRACTORY OSTEOSARCOMA
Emily Slotkin
Favorite
(P 307) ADOLESCENT AND YOUNG ADULT SARCOMA TREATMENT HARMONIZATION: AYA MAP FOR OSTEOSARCOMA
Emily Slotkin
Favorite
Smith, Caroline

UT Southwestern Medical Center
(P 035) RISK FACTORS FOR BONY METASTASES IN PEDIATRIC OSTEOSARCOMA PATIENTS
Caroline Smith
Favorite
Smith, Kaitlyn

Atrium Health - Levine Children's Hospital
(P 246) PANOBINOSTAT DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Kaitlyn Smith
Favorite
Smith, Myles

Sarcoma Unit, Royal Marsden Hospital
(P 085) RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Myles Smith
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Myles Smith
Favorite
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Myles Smith
Favorite
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Myles Smith
Favorite
Smolle, Maria Anna

Department of Orthopaedics and Trauma, Medical University of Graz, Austria
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Maria Anna Smolle
Favorite
Smrke, Alannah

BC Cancer
(P 074) EWING SARCOMA AND RHABDOMYOSARCOMA PATIENT OUTCOME VARIATIONS BASED ON TREATMENT CENTRE VOLUME
Alannah Smrke
Favorite
(P 152) FINAL RESULTS OF GEMMK: A PHASE I TRIAL OF GEMCITABINE AND PEMBROLIZUMAB IN PATIENTS WITH LEIOMYOSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Alannah Smrke
Favorite
Snelling, Sarah

University of Oxford
(P 252) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Sarah Snelling
Favorite
Snyder, Benjamin

Indiana University/Riley Hospital for Children
(P 226) ASSESSING PREDICTIVE VALUE OF RNA-SEQ OF B4GALNT1 AND ST8SIA1 AS BIOMARKERS OF GD2 EXPRESSION IN PEDIATRIC SARCOMAS
Benjamin Snyder
Favorite
Sobczuk, Pawel

Maria Sklodowska-Curie National Research Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma
(P 168) SYSTEMIC INFLAMMATION INDEX (SII) AS INDEPENDENT PREDICTIVE FACTOR IN PATIENTS WITH L-SARCOMA TREATED WITH TRABECTEDIN - ANALYSIS OF REAL-WORLD EVIDENCE FROM A REFERENCE CENTER
Pawel Sobczuk
Favorite
(P 169) WHAT IS THE MOSTAPPROPRIATE STUDY ENDPOINT FOR PHASE IICLINICAL TRIALS IN SOFT TISSUE SARCOMA? - CHARACTERISTIC OF THE CURRENT LANDSCAPE OF PHASE II TRIALS
Pawel Sobczuk
Favorite
Sochacki, Andrew

START Midwest
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Andrew Sochacki
Favorite
Soffientini, Cesare

Fondazione IRCCS Istituto Nazionale dei Tumori
(P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Cesare Soffientini
Favorite
Solis-Hernandez, Maria Pilar

Hospital Universitario Central de Asturias
(P 161) PALBOSARC: A PHASE II TRIAL OF PALBOCICLIB IN ADVANCED SARCOMA OVEREXPRESSING CDK4 GENE EXCLUDING DEDIFFERENTIATED LIPOSARCOMA (DD LPS): A STUDY FROM THE SPANISH GROUP FOR RESEARCH ON SARCOMA (GEIS).
Maria Pilar Solis-Hernandez
Favorite
Somaiah, Neeta

The University of Texas MD Anderson Cancer Center
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Neeta Somaiah
Favorite
Somarelli, Jason

Department of Medicine, Duke University
(P 171) CANINE-DERIVED OSTEOSARCOMA ORGANOIDS MODEL TUMOR HETEROGENEITY AND CHEMOTHERAPY RESISTANCE
Jason Somarelli
Favorite
Sommer, Josh

Chordoma Foundation
(P 013) A PHASE 2 TRIAL OF CETUXIMAB FOR PATIENTS WITH LOCALLY ADVANCED/METASTATIC CHORDOMA
Josh Sommer
Favorite
Song, Paul

NKGen Biotech Inc
(P 138) SUSTAINED REMISSION/DISEASE CONTROL USING AUTOLOGOUS ENHANCED NATURAL KILLER CELLS PLUS AN IMMUNE CHECKPOINT INHIBITOR AS TREATMENT FOR RARE CHEMOTHERAPY-RESISTANT ADVANCED SOFT TISSUE SARCOMAS
Paul Song
Favorite
Sophie, Cotteret

Gustave Roussy
(P 060) TOWARD A NEW GENOMIC AND CLINICO-PATHOLOGIC CLASSIFICATION OF UTERINE ADENOSARCOMAS
Cotteret Sophie
Favorite
Soragni, Alice

University of California, Los Angeles
(P 183) OSTEOSARCOMA ORGANOIDS RECAPITULATE TUMOR CHARACTERISTICS AND MAINTAIN HETEROGENEITY
Alice Soragni
Favorite
(P 184) PAN-SARCOMA ORGANOID SCREENING PIPELINE
Alice Soragni
Favorite
Sousa, Nuno

Medical Oncology Department, IPO Porto FG, EPE, Rua António Bernardino de Almeida
(P 107) LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN ADULT PATIENTS WITH TRK FUSION SARCOMAS
Nuno Sousa
Favorite
Spaanderman, Douwe

Erasmus Medical Center Rotterdam
(P 044) AUTOMATIC SEGMENTATION USING DEEP LEARNING TO DISTINGUISH BETWEEN 9 TYPES OF SOFT-TISSUE TUMORS WITH RADIOMICS
Douwe Spaanderman
Favorite
Spadazzi, Chiara

Osteoncology Unit, Bioscience Laboratory, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy
(P 195) THE STRATEGIC ROLE OF 3D CULTURE SYSTEMS AND ZEBRAFISH NEAR-PATIENTS PRECLINICAL PLATFORMS AS PREDICTIVE TOOLS OF CHEMOTHERAPY RESPONSE FOR SARCOMA
Chiara Spadazzi
Favorite
(P 250) SYSTEMIC INFLAMMATORY INDICES IN SECOND LINE SOFT TISSUE SARCOMAS PATIENTS: FOCUS ON LYMPHOCYTE/MONOCYTE RATIO AND TRABECTEDIN ACTIVITY
Chiara Spadazzi
Favorite
Specchia, Cristina

Department of Gynecology and Reproductive Medicine, Humanitas Clinical and Research Center, IRCCS, Rozzano, 20089, Italy.
(P 08) HOW TO DEVELOP AN ADOLESCENT AND YOUNG PROGRAM IN AN ADULT CANCER CENTER: THE HUMANITAS RESEARCH HOSPITAL EXPERIENCE
Cristina Specchia
Favorite
Spira, Alexander

Virginia Cancer Specialist
(P 313) A PHASE 2, MULTICENTER, OPEN-LABEL BASKET TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH MALIGNANT SOLID TUMORS HARBORING PATHOGENIC INACTIVATING ALTERATIONS IN TSC1 OR TSC2 GENES (PRECISION I)
Alexander Spira
Favorite
Spitz, Douglas

Free Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, IA
(P 160) NEOADJUVANT PHARMACOLOGICAL ASCORBATE WITH CONCURRENT RADIATION IN LOCALLY ADVANCED SOFT-TISSUE SARCOMA OF EXTREMITY/TRUNK AND RETROPERITONEUM
Douglas Spitz
Favorite
(P 178) HIGH FREQUENCY OF NAPRT-SILENCING IN NEUROBLASTOMA AND RHABDOMYSARCOMA CONFERS SENSITIVITY TO TARGETING OF NAD+ METABOLISM USING NAMPT INHIBITORS
Douglas Spitz
Favorite
Spolverato, Gaya

University of Padova
(P 220) PROMOTING GLOBAL EDUCATION IN THE FIELD OF RETROPERITONEAL SARCOMA: THE FIRST OPEN-ACCESS EDUCATIONAL WEBINAR SERIES BY THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP
Gaya Spolverato
Favorite
Squires, Malcolm

Atrium Health/Levine Cancer Institute
(P 261) CLINICAL FEATURES AND TREATMENT OUTCOMES OF PATIENTS WITH DESMOID TUMORS: A LARGE SINGLE INSTITUTION RETROSPECTIVE SERIES
Malcolm Squires
Favorite
Srinivasaraghavan, Aniruth

Texas A&M School of Medicine
(P 248) RESULTS OF A NEOADJUVANT REGIMEN USING A FIXED DOSE OF ADRIAMYCIN AS AN ELECTRON AFFINIC AGENT WITH 27GY FOLLOWED BY WIDE LOCAL RESECTION OF SOFT TISSUE SARCOMAS
Aniruth Srinivasaraghavan
Favorite
Srinivas, Sujay

Tata Memorial Centre
(P 03) DEMOGRAPHICS, PRACTICE PATTERNS, CHALLENGES AND OUTCOMES OF SYNOVIAL SARCOMA PATIENTS FROM A TERTIARY CARE CENTRE FROM A LARGE LOW-MIDDLE INCOME COUNTRY
Sujay Srinivas
Favorite
(P 09) OUTCOMES, PROGNOSTIC FACTORS AND TREATMENT COMPLIANCE IN OSTEOSARCOMA CASES TREATED WITH AN INDIGENOUS, LOW-COST PROTOCOL, OGS-12, IN A TERTIARY CARE CANCER CENTRE IN INDIA
Sujay Srinivas
Favorite
Staals, Eric

IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
(P 038) TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT (TOPP): 2-YEAR OBSERVATIONAL SUB-ANALYSIS OF AGE AND PATIENT-REPORTED OUTCOMES FROM AN EU/US PROSPECTIVE REGISTRY
Eric Staals
Favorite
Stacchiotti, Silvia

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
(P 01) ANTITUMOR ACTIVITY OF CYTOTOXIC AND TARGETED AGENTS IN A PATIENT-DERIVED XENOGRAFT (PDX) OF DESMOPLASTIC SMALL ROUND CELL TUMOR (DSRCT) HIGHLIGHTS THE IRINOTECAN-TRABECTEDIN COMBINATION
Silvia Stacchiotti
Favorite
(P 016) ACTIVITY OF CHEMOTHERAPY IN MESENCHYMAL CHONDROSARCOMA: A MULTICENTRE RETROSPECTIVE ANALYSIS WITHIN THE ITALIAN SARCOMA GROUP
Silvia Stacchiotti
Favorite
(P 052) PATHOLOGICAL AND RADIOLOGICAL RESPONSE AFTER NEOADJUVANT TREATMENTS IN PRIMARY RESECTABLE MYXOFIBROSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA OF THE EXTREMITIES AND TRUNK WALL
Silvia Stacchiotti
Favorite
(P 102) EFFICACY AND SAFETY OF VIMSELTINIB IN TENOSYNOVIAL GIANT CELL TUMOUR: PHASE 2 EXPANSION
Silvia Stacchiotti
Favorite
(P 170) ANTITUMOR ACTIVITY OF TAZEMETOSTAT AND DOXORUBICIN COMBINATION ON PATIENT-DERIVED PRECLINICAL MODELS OF EPITHELIOID SARCOMA
Silvia Stacchiotti
Favorite
(P 188) PRELIMINARY ASSESSMENT OF CIRCULATING INFLAMMATORY CYTOKINES IN EPITHELIOID HEMANGIOENDOTHELIOMA (EHE) PATIENTS AND IN AN EHE PATIENT-DERIVED XENOGRAFT BEFORE AND AFTER DOXORUBICIN AND SIROLIMUS
Silvia Stacchiotti
Favorite
(P 204) PERCEPTIONS AND MANAGEMENT PRACTICES OF SARCOMA EXPERTS ABOUT SOFT TISSUE SARCOMA PATIENTS WITH ISOLATED LUNG METASTASES ACROSS EUROPE
Silvia Stacchiotti
Favorite
(P 292) OUTCOMES IN PLEOMORPHIC LIPOSARCOMA OF THE EXTREMITY AND TRUNK: IS MULTIMODALITY THERAPY INDICATED?
Silvia Stacchiotti
Favorite
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
Silvia Stacchiotti
Favorite
Stalley, Paul

Royal Prince Alfred Hospital
(P 258) TO TREAT OR NOT TO TREAT: AN AUDIT OF INITIAL MANAGEMENT OF PATIENTS WITH DESMOID TUMOURS AT A SPECIALISED CENTRE
Paul Stalley
Favorite
Starmans, Martijn

Erasmus Medical Center
(P 044) AUTOMATIC SEGMENTATION USING DEEP LEARNING TO DISTINGUISH BETWEEN 9 TYPES OF SOFT-TISSUE TUMORS WITH RADIOMICS
Martijn Starmans
Favorite
Statz-Geary, Kurt

University of Miami
(P 07) HETEROGENEITY IN TREATMENT REGIMENS FOR AYA BONE SARCOMAS: A COMPARISON OF OUTCOMES AT A SINGLE SARCOMA CENTER
Kurt Statz-Geary
Favorite
Stea, Baldassarre

Banner University Medical Center Tucson
(P 208) STEREOTACTIC ABLATIVE BODY RADIOTHERAPY FOR PEDIATRIC OSTEOSARCOMA LUNG METASTASES
Baldassarre Stea
Favorite
Steeghs, Neeltje

The Netherlands Cancer Institute
(P 103) GIST PATIENT AND TUMOR CHARACTERISTICS IN REFERENCE CENTERS AND NON-REFERENCE CENTERS: DATA FROM A NATIONWIDE REGISTRY
Neeltje Steeghs
Favorite
Stegmaier, Kimberly

Dana Farber
(P 036) STAG2 LOSS ENCHANCES SENSITIVITY TO DNA DAMAGE YET REDUCES DNA DAMAGE-INDUCED INFLAMMATION IN EWING SARCOMA
Kimberly Stegmaier
Favorite
(P 229) CHARACTERIZING THE MICROSATELLITE-BINDING FUNCTION OF EWS-FLI AND ETV6 IN EWING SARCOMA
Kimberly Stegmaier
Favorite
Stein, James

Children's Hospital Los Angeles
(P 037) SURVIVAL OUTCOMES AND POST-SURGICAL MORBIDITY BASED ON SURGICAL APPROACH TO PULMONARY METASTASECTOMY IN PATIENTS WITH OSTEOSARCOMA
James Stein
Favorite
Stemmer, Amos
(P 257) SELECTIVE INTRA-ARTERIAL DOXORUBICIN-ELUTING EMBOLIZATION FOR DESMOID FIBROMATOSIS: A COMBINED PROSPECTIVE AND RETROSPECTIVE STUDY
Amos Stemmer
Favorite
Stitzlein, Russell

Department of Orthopedic Surgery, University of California Irvine
(P 199) A STUDY OF PRE- AND POST-TREATMENT NEUTROPHIL COUNTS, LYMPHOCYTE COUNTS, AND NEUTROPHIL-TO-LYMPHOCYTE RATIOS IN PATIENTS WITH SOFT TISSUE SARCOMA UNDERGOING RADIOTHERAPY
Russell Stitzlein
Favorite
Stoppiello, Pablo

Unidad de Patología Oncológica Musculo Esquelética, Instituto Nacional de Ortopedia y Traumatología
(P 077) FREEZING IN FLORIDA: ARE WE READY FOR DIVERSITY?
Pablo Stoppiello
Favorite
(P 309) THE ONCOLOGY ORTHOPEDIST ROLE: WHERE DO WE FIT?
Pablo Stoppiello
Favorite
Stosky, Jordan

University of Calgary
(P 205) PREOPERATIVE CHEMORADIATION (MODIFIED EILBER PROTOCOL) VERSUS NEOADJUVANT/ ADJUVANT RADIOTHERAPY FOR SOFT TISSUE EXTREMITY SARCOMAS: A POPULATION BASED ANALYSIS IN ALBERTA
Jordan Stosky
Favorite
Strach, Madeleine

Chris O'Brien Lifehouse
(P 149) CHARACTERISTICS OF PATIENTS WITH BONE AND SOFT TISSUE SARCOMAS REFERRED TO A DEDICATED EARLY PHASE CLINICAL TRIAL CLINIC
Madeleine Strach
Favorite
(P 258) TO TREAT OR NOT TO TREAT: AN AUDIT OF INITIAL MANAGEMENT OF PATIENTS WITH DESMOID TUMOURS AT A SPECIALISED CENTRE
Madeleine Strach
Favorite
Strauss, Dirk

Sarcoma Unit, The Royal Marsden Hospital NHS Foundation Trust
(P 061) UNRAVELLING THE HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT IN STS USING QUANTITATIVE MRI
Dirk Strauss
Favorite
(P 085) RADIATION ASSOCIATED ANGIOSARCOMAS OF THE BREAST: MULTIFOCALITY WARRANTS AGGRESSIVE ONCOLOGICAL STRATEGY
Dirk Strauss
Favorite
(P 218) PRIMARY PELVIC SOFT TISSUE SARCOMAS (PELVISARC): OUTCOMES IN A SERIES OF 401 PATIENTS FROM THE TRANSATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)
Dirk Strauss
Favorite
(P 298) PROGNOSIS OF PATIENTS WITH CUTANEOUS ANGIOSARCOMA AFTER SURGICAL RESECTION WITH CURATIVE INTENT: IS THERE A DIFFERENCE BETWEEN THE SUBTYPES?
Dirk Strauss
Favorite
Strauss, Sandra

University College, London
(P 043) A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Sandra Strauss
Favorite
(P 148) ANALYSIS OF REECUR TRIAL DATA TO EVALUATE POTENTIAL PROGNOSTIC FACTORS IN RECURRENT AND PRIMARY REFRACTORY EWING SARCOMA (RR-ES)
Sandra Strauss
Favorite
(P 252) THE GENOMIC LANDSCAPE OF CLEAR CELL SARCOMA RESEARCH INITIATIVE
Sandra Strauss
Favorite
Streitbürger, Arne

Clinic of Orthopedics, University Hospital Essen, West German Cancer Centre
(P 042) VALUE OF ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALIZED EWING SARCOMA AT THE EXTREMITIES. REPORT FROM THE EWING 2008 TRIAL
Arne Streitbürger
Favorite
Styring, Emelie

Skåne University Hospital
(P 014) A PLETHORA OF DISEASE-ASSOCIATED ALTERATIONS IN OSTEOSARCOMA
Emelie Styring
Favorite
(P 024) GENETIC REARRANGEMENTS IN 12Q-AMPLIFIED OSTEOSARCOMA RESULT IN ECTOPIC GENE EXPRESSION THROUGH TRANSPOSITION OF REGULATORY ELEMENTS AND SELECTIVE AMPLIFICATION
Emelie Styring
Favorite
St-Yves, Hugo

CIUSSS de l'Est-de-l'Île-de-Montréal
(P 054) PROGNOSTIC FACTORS AFFECTING SURVIVAL OF PATIENTS WITH PRIMARY MUSCULOSKELETAL SARCOMAS FOLLOWING PULMONARY METASTASECTOMY
Hugo St-Yves
Favorite
Subbiah, Vivek

The University of Texas MD Anderson Cancer Center
(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Vivek Subbiah
Favorite
(P 269) LANDSCAPE OF GENOMIC ALTERATIONS IN 115 PATIENTS WITH DESMOID FIBROMATOSIS IN THE AACR GENIE REAL WORLD DATABASE: CLINICAL IMPLICATIONS
Vivek Subbiah
Favorite
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
Vivek Subbiah
Favorite
Subhawong, Ty

University of Miami
(P 263) COMPARATIVE EFFECTIVENESS OF SYSTEMIC TREATMENTS IN DESMOID TUMORS
Ty Subhawong
Favorite
Subramanian, Ajay

Stanford University
(P 130) MONITORING SOFT TISSUE SARCOMA RESPONSE TO IMMUNE CHECKPOINT INHIBITION AND CRYOTHERAPY WITH CIRCULATING TUMOR DNA ANALYSIS
Ajay Subramanian
Favorite
Sudhaman, Sumedha

Natera, Inc
(P 047) FEASIBILITY OF A PERSONALIZED AND TUMOR-INFORMED CT-DNA ASSAY IN PATIENTS WITH LEIOMYOSARCOMA
Sumedha Sudhaman
Favorite
Sudo, Kazuki

Department of Medical Oncology, National Cancer Center Hospital
(P 147) ANALYSIS OF INFLAMMATORY BIOMARKERS AS PREDICTORS OF TREATMENT EFFICACY IN SOFT TISSUE SARCOMA TREATED WITH TRABECTEDIN
Kazuki Sudo
Favorite
(P 150) CLINICAL CHARACTERISTICS OF PRIMARY CUTANEOUS AND SUBCUTANEOUS EWING SARCOMA FAMILY OF TUMORS
Kazuki Sudo
Favorite
Sulciner, Megan

Brigham and Women's Hospital/Harvard Medical School
(P 214) EXPERIENCE OF MANAGEMENT FOR LOCALIZED PARATESTICULAR LIPOSARCOMA: A SINGLE INSTITUTION COHORT
Megan Sulciner
Favorite
Sum Hon Mun, Timothy

The Institute of Cancer Research
(P 061) UNRAVELLING THE HETEROGENEITY OF THE IMMUNE MICROENVIRONMENT IN STS USING QUANTITATIVE MRI
Timothy Sum Hon Mun
Favorite
Sundaram, Ranjini

Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT
(P 178) HIGH FREQUENCY OF NAPRT-SILENCING IN NEUROBLASTOMA AND RHABDOMYSARCOMA CONFERS SENSITIVITY TO TARGETING OF NAD+ METABOLISM USING NAMPT INHIBITORS
Ranjini Sundaram
Favorite
Sun, Kaiyu

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080
(P 101) CYTOREDUCTIVE SURGERY FOR METASTATIC GASTROINTESTINAL STROMAL TUMORS TREATED WITH RIPRETINIB: A SINGLE-CENTER ANALYSIS.
Kaiyu Sun
Favorite
Sun, Lei

Cogent Biosciences
(P 320) PEAK STUDY: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS
Lei Sun
Favorite
Sun, Xin

Peking University People’s Hospital
(P 021) DISTINCT GENOMIC FEATURES BETWEEN OSTEOSARCOMAS FIRSTLY METASTASING TO BONE AND TO LUNG
Xin Sun
Favorite
Suo, Libin

Department of Anesthesiology, Peking University International Hospital
(P 211) ANESTHESIA MANAGEMENTS AND POSTOPERATIVE MORTALITIES IN RETROPERITONEAL SARCOMA PATIENTS EXPERIENCING MASSIVE BLOOD TRANSFUSION DURING SURGERIES
Libin Suo
Favorite
Sussman, Carleigh

MSKCC
(P 241) INVESTIGATING THE EVOLUTION OF CELL STATES IN UNDIFFERENTIATED PLEOMORPHIC SARCOMAS USING A GENETICALLY ENGINEERED MOUSE MODEL
Carleigh Sussman
Favorite
Svensson, Liz

Boehringer Ingelheim AB
(P 163) PHASE IA/IB, DOSE-ESCALATION/EXPANSION STUDY OF THE MURINE DOUBLE MINUTE 2–TUMOR PROTEIN 53 ANTAGONIST BI 907828 IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH ADVANCED SOLID TUMORS
Liz Svensson
Favorite
Swallow, Carol

University of Toronto
(P 088) RETHINKING THE MANAGEMENT OF AGGRESSIVE ANGIOMYXOMA: A REPORT FROM FOUR CANADIAN SARCOMA CENTRES.
Carol Swallow
Favorite
(P 180) INVESTIGATING CLINICAL FACTORS ASSOCIATED WITH THE ESTABLISHMENT OF SUCCESSFUL PRIMARY HUMAN SOFT TISSUE SARCOMA CELL LINES
Carol Swallow
Favorite
Sweeney, Kyle

Kansas University Medical Center
(P 276) ASSOCIATION OF THE COVID-19 PANDEMIC WITH SOFT TISSUE SARCOMA CHARACTERISTICS
Kyle Sweeney
Favorite
(P 303) SMALLER SARCOMAS AT HIGHER RISK FOR POSITIVE SURGICAL MARGINS: A PARADOX OF PROGNOSTIC FACTORS
Kyle Sweeney
Favorite
Sydow, Saskia

Lund University
(P 242) LIPOSARCOMAS WITH 12Q AMPLIFICATION - CAN GENETIC CHANGES DISCLOSE THE DEVELOPMENT AND ORIGIN OF RING CHROMOSOMES?
Saskia Sydow
Favorite
Szabo, Sara

Cincinnati Children's Hospital Medical Center
(P 118) SOMATOSTATIN RECEPTOR TYPE 2 EXPRESSION IN SARCOMA
Sara Szabo
Favorite
Szkandera, Joanna

Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz
(P 141) TUMOUR-INFILTRATING IMMUNE CELLS IN SOFT TISSUE SARCOMA. IMPACT ON LOCAL RECURRENCE, DISTANT METASTASIS, AND OVERALL SURVIVAL.
Joanna Szkandera
Favorite
Szuhai, Karoly

LUMC
(P 255) TRUNCATED FOS REDUCES OSTEOGENIC DIFFERENTIATION CAPACITY IN OSTEOID OSTEOMA AND OSTEOBLASTOMA
Karoly Szuhai
Favorite
Szumera-Ciećkiewicz, Anna

Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland & Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
(P 245) MUTATIONAL STATUS OF CHONDROSARCOMA BASED ON TARGETED NEXT-GENERATION SEQUENCING ANALYSIS
Anna Szumera-Ciećkiewicz
Favorite